Results 11 to 20 of about 7,984 (250)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia. [PDF]

Clinicoecon Outcomes Res, 2020
Shafie AA, Ng CH.
europepmc   +3 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yanbu cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Moody El Harby, Ahmed Saeed
doaj   +2 more sources

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Qatar cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Mohamed Hasan Daghash, Jabbar Mubarak Raja, Mohamed Milad   +2 more
doaj   +2 more sources

From Pathophysiology to Treatment: Contemporary Approaches to CFRD in the Pediatric and Adolescent Population. [PDF]

Pediatr Diabetes
Cystic fibrosis‐related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old.
Vuralli D.
europepmc   +2 more sources

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V., Goodwill, Adam, Green, Mark A., Hamilton, LaTonya, Hutchins, Gary D., Mather, Kieren J., Mathias, Carla, Patel, Niral A., Territo, Wendy, Tune, Johnathan D.   +9 more
core   +1 more source

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes - A randomized clinical trial [PDF]

, 2004
OBJECTIVE—Insulin detemir is a soluble long-acting basal insulin analog designed to overcome the limitations of conventional basal insulin formulations.
Abrams, Pascale, Bartley, Paul, Draeger, Eberhard, Hanaire-Broutin, Hélène, Heeg, Jan-Evert, Home, Philip, Hylleberg, Birgitte, Landin-Olsson, Mona,, Lang, Hanne, Lund University., Russell-Jones, David   +10 more
core   +1 more source

Comparison of insulin detemir and insulin glargine in a Basal-Bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial [PDF]

, 2009
Objective: The primary study objective was to determine whether insulin detemir (detemir) was noninferior to insulin glargine (glargine) as the basal insulin in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in terms of glycemic ...
Albright, Bolli, Bruce Bode, Buse, Christoph Koenen, Devries, Garg, Havelund, Heinemann, Heinemann, Heise, Heise, Hermansen, Hougaard, Jehle, Klein, Le Floch, Montgomery, Owens, Pieber, Ratner, Russell-Jones, Simon Heller   +22 more
core   +1 more source

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas [PDF]

, 2013
OBJECTIVEdThis multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without ...
Adetunji, O., Davies, M., Heller, S., Sapin, H., Sreenan, S., Tahbaz, A., Vora, J.   +6 more
core   +1 more source

Insulin therapy and dietary adjustments to normalize glycemia and prevent nocturnal hypoglycemia after evening exercise in type 1 diabetes: a randomized controlled trial [PDF]

, 2014
Introduction Evening-time exercise is a frequent cause of severe hypoglycemia in type 1 diabetes, fear of which deters participation in regular exercise.
Campbell, Matthew, Walker, Mark, Bracken, Richard, Turner, David, Stevenson, Emma, Gonzalez, Javier, Shaw, James, West, Dan   +7 more
core   +4 more sources

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog

Clinical Medicine Insights: Endocrinology and Diabetes, 2010
Insulin detemir is a long-acting basal insulin approved for use in patients with type 1 (T1DM) or type 2 diabetes (T2DM). Insulin detemir has demonstrated equivalent glycemic control and hypoglycemic risk when compared to insulin glargine, and insulin ...
Jason R. Young, Carrie Mcadam-Marx
doaj   +1 more source